February 10, 2021
1 min read
Gemini Therapeutics completed enrollment in a phase 2a study investigating safety and tolerability of GEM103 in dry age-related macular degeneration, according to a press release.
ReGAtta is an ongoing, multicenter, open-label, multiple ascending dose study of a recombinant form of the human complement factor H (CFH) protein in patients with dry AMD and CFH loss-of-function gene variants, the release said.
“Our strategy is to provide an intravitreal recombinant human factor H in patients with gene variants resulting in loss of function of their own CFH,” Marc E. Uknis, MD, FACS, chief medical officer of Gemini Therapeutics, said in the release.
In addition to safety and tolerability, ReGAtta will evaluate intraocular pharmacokinetics and disease-related biomarkers, which will help develop a late-stage program.
The company anticipates topline data from the trial this year.
The Link LonkFebruary 10, 2021 at 11:27PM
https://www.healio.com/news/ophthalmology/20210210/gemini-completes-enrollment-in-phase-2a-trial-of-dry-amd-therapy
Gemini completes enrollment in phase 2a trial of dry AMD therapy - Healio
https://news.google.com/search?q=dry&hl=en-US&gl=US&ceid=US:en
No comments:
Post a Comment